Evaluating the Role of PI3K Inhibitors in Follicular Lymphoma: Highlighting the Diversity and Impact of an Emerging Therapeutic Class

Evaluating the Role of PI3K Inhibitors in Follicular Lymphoma: Highlighting the Diversity and Impact of an Emerging Therapeutic Class

On-Demand Webcast
Chair

John P. Leonard, MD
Weill Cornell Medicine
New York, New York

Faculty

Peter Martin, MD
Weill Cornell Medicine
New York, New York

Target Audience

Designed for hematologists and hematologic oncologists, medical, radiation, and surgical oncologists, and other healthcare professionals (e.g., physicians, physicians-in-training, oncology nurses, nurse practitioners, pharmacists, physician assistants) who are involved and/or interested in the treatment of patients with hematologic malignancies.

Overview

Recently, phosphoinositide 3-kinase (PI3K) inhibitors have emerged as a viable therapeutic class in relapsed/refractory FL. The prototypical PI3K inhibitor idelalsib as well as the newer agent copanlisib are now approved in this setting, and other PI3K inhibitors are in various stages of clinical development. However, these agents differ significantly in terms of their specificity for PI3K isoforms; adverse effect profiles; dosing and administration; and efficacy, safety, and tolerability in the management of FL. Thus, healthcare providers must be equipped with a thorough understanding of the within-class distinctions among PI3K inhibitors as well as the clinical data surrounding their use in FL, to make informed therapeutic decisions in relapsed/refractory FL management.

This on-demand web archive is initiated to address knowledge and practice gaps among physicians, NPs, and PAs pertaining to various treatment options in FL.


Objectives
  1. Highlight the clinical challenges posed by standard chemo-immunotherapeutic approaches to relapsed/refractory FL
  2. Distinguish among available and emerging PI3K inhibitors with respect to their isoform specificity, associated adverse effect profiles, dosing and administration, and clinical efficacy, safety, and tolerability in the management of FL
  3. Integrate the latest clinical data, agent-specific considerations, and adverse effect management strategies into FL treatment plans that incorporate the use of PI3K inhibitors as appropriate

Release Date: October 31, 2018

Expiration Date: October 31, 2019

Hardware/Software Requirements

The evaluation is accessible after the activity via a PC (Windows 7 or newer) or Mac (Mac OS 10.6 or later) computer with current versions of the following browsers: Internet Explorer, Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. Please direct technical questions to webmaster@naccme.com.

Support

Supported by educational grants from: Bayer HealthCare Pharmaceuticals, Inc. and Verastem Oncology

Accreditation


In support of improving patient care, this activity has been planned and implemented by North American Center for Continuing Medical Education (NACCME) and Imedex. NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

CME

NACCME designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credit™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PHYSICAN ASSISTANTS

NACCME has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 credit(s).

PAs should only claim credit commensurate with the extent of their participation.

CNE

This continuing nursing education activity awards 0.75 contact hour.

Provider approved by the California Board of Registered Nursing, Provider #13255 for 0.75 contact hour.

CPE

This knowledge-based activity (JA0006201-9999-18-222-H01-P) is approved for 0.75 contact hour (0.0075 CEUs) of continuing pharmacy education.

This educational activity is a knowledge-based activity.

ACPE Credit Policy

Your official record of ACPE credit will be generated through the CPE Monitor System. The certificate printed from this website after completing the evaluation for this activity is for personal tracking purposes only.

Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended. Please note that you must complete the activity evaluation within 60 days of a live activity or within 60 days of beginning the evaluation for an enduring activity. Under ACPE Policy, NACCME will not be able to report your activity completion to CPE Monitor after this 60-day period.

Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity accredited by NACCME may contact the Senior Manager, Accreditation & Compliance, NACCME, in writing at 104 Windsor Center Drive, East Windsor, NJ 08520. The Senior Manager, Accreditation & Compliance will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Senior Director, Accreditation and Compliance, NACCME, may be made for a second level of review.

Planning Committee

The planning committee comprises John P. Leonard, MD, Peter Martin, MD; and Chris Bolwell, Monalisa Singh, and Susan Yarbrough, Imedex.

Financial Disclosure and Conflicts of Interest

According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

John P. Leonard, MD has served as a consultant for ADC Therapeutics, AstraZeneca, Bayer, Bristol-Myers Squibb, Bio Test, Celgene, Epizyme, Gilead, Juno, Karyopharm, MEI Pharma, Novartis, Pfizer, Roche, Surto, and United Therapuetics.

Peter Martin, MD has served as a consultant for Acerta, Genentech, Gilead, Janssen, Kite, and Seattle Genetics.

Chris Bolwell discloses that he holds shares of stock of GlaxoSmithKline.

Monalisa Singh and Susan Yarbrough disclosed no relevant financial relationships with any commercial interests.

NACCME requires faculty to inform participants whenever off-label/unapproved uses of drugs and/or devices are discussed in their presentations.

Disclosure of off-label/unapproved uses of drugs and/or devices will be provided prior to the symposium.

Privacy Policy

NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. NACCME and our joint sponsors will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2018 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education. The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.